218 related articles for article (PubMed ID: 22933705)
1. Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.
Gerber DE; Gupta P; Dellinger MT; Toombs JE; Peyton M; Duignan I; Malaby J; Bailey T; Burns C; Brekken RA; Loizos N
Mol Cancer Ther; 2012 Nov; 11(11):2473-82. PubMed ID: 22933705
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
[TBL] [Abstract][Full Text] [Related]
3. Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis.
Russell MR; Liu Q; Fatatis A
Clin Cancer Res; 2010 Oct; 16(20):5002-10. PubMed ID: 20813817
[TBL] [Abstract][Full Text] [Related]
4. Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer.
Reinmuth N; Liersch R; Raedel M; Fehrmann F; Fehrmann N; Bayer M; Schwoeppe C; Kessler T; Berdel W; Thomas M; Mesters RM
Int J Cancer; 2009 Apr; 124(7):1535-44. PubMed ID: 19115205
[TBL] [Abstract][Full Text] [Related]
5. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.
Roh JW; Huang J; Hu W; Yang X; Jennings NB; Sehgal V; Sohn BH; Han HD; Lee SJ; Thanapprapasr D; Bottsford-Miller J; Zand B; Dalton HJ; Previs RA; Davis AN; Matsuo K; Lee JS; Ram P; Coleman RL; Sood AK
Clin Cancer Res; 2014 May; 20(10):2740-50. PubMed ID: 24634380
[TBL] [Abstract][Full Text] [Related]
6. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma.
Matsuo K; Nishimura M; Komurov K; Shahzad MM; Ali-Fehmi R; Roh JW; Lu C; Cody DD; Ram PT; Loizos N; Coleman RL; Sood AK
Gynecol Oncol; 2014 Jan; 132(1):166-75. PubMed ID: 24183729
[TBL] [Abstract][Full Text] [Related]
7. GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo.
Zhang Z; Ren X; Lu X; Wang D; Hu X; Zheng Y; Song L; Pang H; Yu R; Ding K
Cancer Lett; 2016 May; 375(1):172-178. PubMed ID: 26940138
[TBL] [Abstract][Full Text] [Related]
8. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.
Stock P; Monga D; Tan X; Micsenyi A; Loizos N; Monga SP
Mol Cancer Ther; 2007 Jul; 6(7):1932-41. PubMed ID: 17604334
[TBL] [Abstract][Full Text] [Related]
9. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
[No Abstract] [Full Text] [Related]
10. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells.
Donnem T; Al-Saad S; Al-Shibli K; Andersen S; Busund LT; Bremnes RM
J Thorac Oncol; 2008 Sep; 3(9):963-70. PubMed ID: 18758297
[TBL] [Abstract][Full Text] [Related]
11. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
Loizos N; Xu Y; Huber J; Liu M; Lu D; Finnerty B; Rolser R; Malikzay A; Persaud A; Corcoran E; Deevi DS; Balderes P; Bassi R; Jimenez X; Joynes CJ; Mangalampalli VR; Steiner P; Tonra JR; Wu Y; Pereira DS; Zhu Z; Ludwig DL; Hicklin DJ; Bohlen P; Witte L; Kussie P
Mol Cancer Ther; 2005 Mar; 4(3):369-79. PubMed ID: 15767546
[TBL] [Abstract][Full Text] [Related]
12. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy.
Liang M; Wang B; Schneider A; Vainshtein I; Roskos L
AAPS J; 2020 Nov; 23(1):4. PubMed ID: 33210183
[TBL] [Abstract][Full Text] [Related]
13. Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma.
Tejada ML; Yu L; Dong J; Jung K; Meng G; Peale FV; Frantz GD; Hall L; Liang X; Gerber HP; Ferrara N
Clin Cancer Res; 2006 May; 12(9):2676-88. PubMed ID: 16675559
[TBL] [Abstract][Full Text] [Related]
14. Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC.
Kilvaer TK; Rakaee M; Hellevik T; Vik J; Petris L; Donnem T; Strell C; Ostman A; Busund LR; Martinez-Zubiaurre I
Sci Rep; 2019 Jul; 9(1):10163. PubMed ID: 31308421
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
[TBL] [Abstract][Full Text] [Related]
17. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma.
Govaere O; Petz M; Wouters J; Vandewynckel YP; Scott EJ; Topal B; Nevens F; Verslype C; Anstee QM; Van Vlierberghe H; Mikulits W; Roskams T
Oncogene; 2017 Nov; 36(47):6605-6616. PubMed ID: 28783171
[TBL] [Abstract][Full Text] [Related]
18. Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.
Jiang Y; Allen D; Kersemans V; Devery AM; Bokobza SM; Smart S; Ryan AJ
Lung Cancer; 2015 Nov; 90(2):191-8. PubMed ID: 26323213
[TBL] [Abstract][Full Text] [Related]
19. Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas.
Song EJ; Ashcraft KA; Lowery CD; Mowery YM; Luo L; Ma Y; Campos LDS; Cardona DM; Stancato L; Kirsch DG
EBioMedicine; 2019 Feb; 40():224-230. PubMed ID: 30711517
[TBL] [Abstract][Full Text] [Related]
20. Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.
Ehnman M; Missiaglia E; Folestad E; Selfe J; Strell C; Thway K; Brodin B; Pietras K; Shipley J; Östman A; Eriksson U
Cancer Res; 2013 Apr; 73(7):2139-49. PubMed ID: 23338608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
